- Home
- NTRB vs DXR Comparison
NTRB vs DXR Comparison
Compare NTRB & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | DXR |
|---|---|---|
| Founded | 2016 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.0M | 61.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NTRB | DXR |
|---|---|---|
| Price | $4.41 | $13.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $13.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 65.4K | 3.5K |
| Earning Date | 12-11-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $2,278,321.00 | $66,306.00 |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | ★ N/A | $39.82 |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $3.90 | $6.55 |
| 52 Week High | $11.78 | $14.76 |
Technical Indicators
Market Signals| Indicator | NTRB | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 52.75 |
| Support Level | $4.33 | $13.20 |
| Resistance Level | $4.61 | $14.76 |
| Average True Range (ATR) | 0.41 | 0.54 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 2.88 | 60.74 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.